Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Feb 6, 2017
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Singleton pregnancy
- • Gestational age 34 weeks 0 days to 37 weeks 0 days at time of enrollment
- • Dating of pregnancy by last menstrual period consistent with an ultrasound, ultrasound \<21 weeks and 6 days of gestation, or known date of conception in the setting of in vitro fertilization
- • No known major anomalies (anomalies requiring surgery antenatally or in the neonatal period, anomalies not compatible with life as determined by the physician)
- • FGR defined as estimated fetal weight (EFW) \< 10th percentile by Hadlock formula with normal umbilical artery Doppler studies and normal amniotic fluid
- Exclusion Criteria:
- • Known major fetal anomalies
- • Multiple gestation or selective reduction of multiple gestation after 14 weeks
- • Previous stillbirth at term
- * Indications for delivery at \<39 weeks. Common examples include:
- • Placenta previa
- • Placenta accreta
- • Vasa previa
- • History of classical cesarean section or myomectomy
- • Human immunodeficiency virus (HIV)
- • Oligohydramnios (low amniotic fluid, defined as maximum vertical pocket \<2.0cm)
- * High-risk pregnancy as determined by the physician. Common examples include:
- • Pre-gestational diabetes or gestational diabetes on medication
- • Chronic hypertension on medication
- • Maternal cardiac disease
- • Asthma requiring oral steroids during pregnancy
- • Chronic renal disease
- • Antiphospholipid syndrome
- • Hyperthyroidism
- • Prior stillbirth
- • Systemic lupus erythematous
- • Hemoglobinopathies such as sickle cell disease
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Patients applied
Trial Officials
Baha M Sibai, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials